Original ResearchRetrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged ≥65 years with rheumatoid arthritis
References (18)
- et al.
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
J Clin Epidemiol
(1993) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
J Chronic Dis
(1987) - et al.
New drugs for rheumatoid arthritis
N Engl J Med
(2004) - et al.
Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population
Am J Manag Care
(2002) - et al.
Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit
J Manag Care Pharm
(2004) - et al.
Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate
Am J Manag Care
(2003)
Cited by (31)
Economic Burden of Rheumatic Diseases
2016, Kelley and Firestein's Textbook of Rheumatology: Volumes 1-2, Tenth EditionCost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: A retrospective cohort study
2014, Clinical TherapeuticsCitation Excerpt :Other administrative claims analyses have reported that adalimumab and infliximab were associated with higher rates of dose escalation than was etanercept.10,11,16,17 Dose escalation is associated with higher treatment costs, leading to increased drug costs.10,11,16,17 Although claims-based studies provide information on drug utilization that takes into account varying dosages by disease, dosage changes, and the effects of varying compliance in clinical practice,14 the use of pharmacy benefits–management (PBM) data has several advantages.
Economic Burden of Rheumatic Diseases
2012, Kelley's Textbook of Rheumatology: Volume 1-2, Ninth EditionAssociation between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: Analysis of an administrative-claims database
2011, Metabolism: Clinical and ExperimentalCitation Excerpt :These prescriptions encompass paid-facility, professional-service, and retail (ie, outpatient) pharmacy claims for the commercially insured, Medicaid, and Medicare populations. The Ingenix I3 database is representative of the US population. [14-16]. A retrospective database analysis was performed on patients at least 20 years old who were continuously enrolled for at least 36 months in the I3 database with a diagnosis of T2DM (International Classification of Diseases, Ninth Revision [ICD-9]) and who were on active treatments with AHAs.
Impact of etanercept on the costs of rheumatoid arthritis (RA) results from a French observational study
2008, Revue du Rhumatisme (Edition Francaise)Impact of etanercept on the costs of rheumatoid arthritis (RA): Results from a French observational study
2008, Joint Bone SpineCitation Excerpt :In spite of factors limiting comparison between previous studies and the present study, one can underline that the annual average direct cost per patient estimated in two reviews published in 2000 were 5425$ [5] and 5720$ [6], and 4003€ in a French study on 1109 patients [7], that is close to the annual costs per patient obtained in our study for patients before treatment by etanercept (5142€). According to a 2005 retrospective American study concerning patients treated by etanercept, the annual average direct medical cost of treatment (hospitalization excluded) obtained from two bases of reimbursement is 12,159$ and 14,297$ [8]. In a 2003 study on 7527 patients, of whom 1880 patients under biotherapy during the last 6 months of the study, annual direct medical cost for patients under biotherapy was 19,016$ versus 6164$ for patients not receiving biotherapy [9]; and a valuation close to these annual direct medical costs is (19,616€) provided by a French study, from the point of view of the payer, on 28 patients, during 52 weeks [10].